Shares of Bristol Myers Squibb Co. BMY rose 3.67% to $57.88 Monday, on what proved to be an all-around mixed trading session ...

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

Bristol Myers said about 5% to 7% of people with metastatic colorectal cancer have microsatellite instability-high or mismatch-repair-deficient tumors, adding that these patients are less likely to ...

Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...

In a regulatory filing on Friday night, Bristol Myers (BMY) disclosed that its CEO Christopher Boerner bought 2K shares of common stock on ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid long-term pick despite short-term risks.